Current stock page

Stock Analysis

NewAmsterdam Pharma Company N.V. (NAMS) Stock Analysis

NewAmsterdam Pharma Company N.V. (NAMS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

NAMS Stock Analysis Summary

NewAmsterdam Pharma Company N.V. (NAMS) currently has an AIQ Score of 41/100, indicating a bearish setup. Quality is the strongest factor at 58/100. Momentum is the weakest current factor at 22/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

NAMS at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$20.14
AIQ Score41/100
Overall ViewBearish
Technical Analysis ConsensusNeutral
Market Cap$2.5B
P/E Ratio (TTM)-11.78
Forward P/E—
EPS (Q3 FY2026)-$0.14
Revenue (Q3 FY2026)$19.16M
Dividend Yield (TTM)0.00%
Beta1.43
Volume1.67M
52-week range$17.90-$42.21
RSI 1447.28
50-Day SMA$21.53
200-Day SMA$29.16
Analyst Price Target$61.00
Next EarningsFeb 17, 2027
As of Nov 13, 2026 · Market close

NAMSNewAmsterdam Pharma Company N.V.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$20.14+$0.17 (+0.85%)

Latest quote

  • Momentum
    22
  • Value
    42
  • Quality
    58
  • Risk resilience
    48
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

NAMS Stock Analysis Summary

NewAmsterdam Pharma Company N.V. (NAMS) currently has an AIQ Score of 41/100, indicating a bearish setup. Quality is the strongest factor at 58/100. Momentum is the weakest current factor at 22/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, NAMS has AIQ Score of 41/100 with Quality base of 58/100 and fading Momentum at 22/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (58/100) leads while Momentum (22/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 0.85% stock move · NAMS classified in Biotechnology.

Current Evidence

BearishNAMS is in a bearish AIQ regime; Quality is the strongest visible factor at 58/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is NAMS Bullish or Bearish Right Now?

NAMS currently has a bearish overall setup. Quality is the strongest factor at 58/100, while Momentum is weakest at 22/100. The current evidence suggests a bearish setup.

Bull Case
  • - Analyst target implies +202.88% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 42/100.
  • - Momentum is weak at 22/100.
  • - Risk Resilience is weak at 48/100.
  • - Price is -30.92% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (22 vs 16).

Current Consensus

NAMS's Technical Analysis Consensus is currently Neutral, with 16 buy, 8 neutral, and 22 sell votes. NAMS's 14-day RSI is 47.28, which places the stock in a neutral momentum range. NAMS's beta is 1.43, indicating greater market sensitivity than the broad market.

Signal Confidence
Moderate agreement

What Changed in NAMS?

The largest recent change in NAMS is Momentum moving up by 4.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+4.0
Quality
+1.0
Risk
+0.0

What Would Change the NAMS Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

NAMS Decision Framework

Public evidence layers, setup checks, and risk context for NewAmsterdam Pharma Company N.V..

NewAmsterdam Pharma Company N.V. (NAMS) Stock Analysis

NewAmsterdam Pharma Company N.V. has an AIQ Score of 41/100 in a Bearish regime. Quality is strongest at 58/100. Beta is 1.43, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextNAMS is in a Bearish AIQ regime with score 41/100.
Signal ConflictThe primary conflict is that quality leads at 58/100 while momentum lags at 22/100.
Factor EvidenceMomentum 22/100 · Value 42/100 · Quality 58/100 · Risk 48/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Quality is the strongest factor at 58/100.

TimingFail

Momentum is 22/100 and RSI (14) is 47.3.

Regime fitFail

NAMS is in a Bearish regime at 41/100.

Risk controlFail

Risk factor is 48/100 with beta 1.43 and annual volatility 53.82%.

ConflictWait

Current conflict: quality leads at 58/100 while momentum lags at 22/100.

AIQ Score
41/100
Price
$20.14
Beta
1.43
RSI (14)
47.3

NAMS Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

NAMS Fundamentals

NAMS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$19.16M
Net income
-$17.39M
Free cash flow
-$39.95M
View full NAMS fundamental analysis

NAMS Technical Analysis

NAMS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Neutral
RSI 14
47.28
Price vs SMA-50
-6.44%
View full NAMS technical analysis

NAMS Stock Catalysts

Track NAMS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 17, 2027
Analyst target
$61.00
News items
0
View NAMS earnings and stock catalysts

NAMS Dividend Analysis

NAMS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View NAMS dividend history and analysis

NAMS Financial Data

NAMS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$19.16M
EPS
-$0.14
Periods
8
View NAMS financials

NAMS Risk Analysis

NAMS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.43
Risk score
48/100
1Y volatility
53.82%
View NAMS risk analysis

NAMS Stock News

NAMS stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read NAMS stock news

NAMS vs Biotechnology Peers

Current peer cohort: NAMS · NBIX · NKTR · NRIX · NVAX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
NAMS
Current stock
41/10042/10022/10048/100-0.9153.82%Current
NBIX
Neurocrine Biosciences, Inc.
74/10077/10070/10069/1000.4935.22%NAMS vs NBIX
NKTR
Nektar Therapeutics
39/10047/10025/10041/100-0.1184.03%NAMS vs NKTR
NRIX
Nurix Therapeutics, Inc.
65/10094/10050/10040/1000.6467.30%NAMS vs NRIX
NVAX
Novavax, Inc.
——77/10038/1000.5673.62%NAMS vs NVAX
Pairwise Compare links: NBIX · NKTR · NRIX · NVAXNAMS vs NBIXNAMS vs NKTRNAMS vs NRIXNAMS vs NVAXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a NAMS stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for NAMS: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-11.78
As of Nov 13, 2026
Revenue growth
5406.90%
Gross margin
97.84%
Current debt / equity
0
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$19.16M
Quarter net income
-$17.39M
Quarter free cash flow
-$39.95M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
47.28
MACD
-0.57

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
48/100
Beta
1.43
Annual volatility
53.82%
Max drawdown
-54.43%

NAMS Stock FAQ

What is NAMS stock price today?

NewAmsterdam Pharma Company N.V.'s current stock price is $20.14. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is NAMS bullish or bearish right now?

NAMS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is NAMS's market cap?

NAMS's market cap is $2.5B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is NAMS's current P/E ratio?

NAMS's current P/E ratio is -11.78 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is NAMS's RSI?

NAMS's 14-day RSI is 47.28 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is NAMS above its 50-day and 200-day moving averages?

NAMS is -6.44% from its 50-day SMA and -30.92% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is NAMS's next earnings date?

NAMS's next earnings date is currently listed as Feb 17, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does NAMS pay a dividend?

NAMS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.